Avalo Therapeutics, Inc. (AVTX)

Market Cap	122.57M
Revenue (ttm)	820,000
Net Income (ttm)	-8.14M
Shares Out	11.24M
EPS (ttm)	-75.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	49,260
Open	11.14
Previous Close	11.05
Day's Range	10.36 - 11.14
52-Week Range	3.95 - 34.46
Beta	1.03
Analysts	Buy
Price Target	35.00 (+221.1%)
Earnings Date	Nov 7, 2024

About AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company’s drug candidates include AVTX-009, an Anti-IL-1β monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory dis...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2015
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTX
• Website: https://www.avalotx.com

Financial Performance

In 2023, Avalo Therapeutics's revenue was $1.92 million, a decrease of -89.34% compared to the previous year's $18.05 million. Losses were -$31.54 million, -24.28% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for AVTX stock is "Buy." The 12-month stock price forecast is $35.0, which is an increase of 221.10% from the latest price.

Price Target

$35.0

(221.10% upside)

Analyst Consensus: Buy